Efficacy and safety of low‐dose rifabutin‐based 7‐day triple therapy as a third‐ or later‐lineHelicobacter pylorieradication regimen

• DOI: 10.1111/hel.12900
• Publication Date: 2022-05-29T18:08:56Z
• Authors: Kazumi Inokuchi; Hideki Mori; Juntaro Matsuzaki; Kenro Hirata; Yosuke Harada; Yoshimasa Saito; Hidekazu Suzuki; Takanori Kanai; Tatsuhiro Masaoka
• Keywords: Rifabutin; Regimen; Esomeprazole; Urea breath test

Rifabutin-based regimens are used as rescue therapy for refractory Helicobacter pylori infection; however, the duration which treatment is required and side effects concerning. This study assessed efficacy safety of 7-day rifabutin, amoxicillin, vonoprazan triple third- or later-line H. infection.Patients who did not respond to second-line were enrolled. After infection was confirmed with culture method, patients received rifabutin-containing (20 mg b.i.d., 500 amoxicillin q.i.d., 150 rifabutin q.d.) 7 days. Twelve weeks after eradication therapy, successful using a 13 C urea breath test stool antigen test. The results obtained from our previous that reported 10-day 14-day esomeprazole based fourth-line treated historical control. We determined minimum inhibitory concentrations rifabutin. also evaluated whether positive mutation rpoB gene.Intention-to-treat per-protocol analyses showed regimen resulted in high rate (91.2%, 95% CI: 84%-99% 92.7%, 86%-100%, respectively). Adverse events occurred 31.6% patients, two discontinued therapy.This first evaluate low-dose rifabutin-based amoxicillin. Our suggest effective safe regimen. To clarify what component this critical, subsequent studies factorial design (comparing vonoprazan-amoxicillin dual vs. vonoprazan-rifabutin therapy) will be needed.